Skip to main content

Cardiovascular disorders

07-07-2023 | Type 2 diabetes | News

New atherothrombotic risk score for type 2 diabetes

The TIMI Risk Score for Atherothrombosis in Diabetes categorises risk of myocardial infarction or stroke in people with type 2 diabetes.

06-21-2023 | Cardiovascular disorders | News

Non-fasting remnant cholesterol shows mixed prognostic value for CVD by diabetes status

Real-world study data show that non-fasting remnant cholesterol levels are associated with a significantly increased risk for CVD in people without diabetes, with a similar, but nonsignificant, trend observed in those with diabetes.

04-24-2023 | Heart failure | News

Prescription NSAID use may trigger heart failure in type 2 diabetes

A case-crossover study supports a link between use of non-steroidal anti-inflammatory drugs and development of heart failure in people with type 2 diabetes.

02-08-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

12-20-2022 | Dapagliflozin | News

Dapagliflozin on way to EC approval for all heart failure

Click through to read more on this announcement

12-06-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.

11-21-2022 | Cancer | News

Type 2 diabetes linked to advanced stage at cancer diagnosis

Having type 2 diabetes increases a person’s risk for a cancer being already metastatic at the point of diagnosis, shows an EPIC analysis.

Human heart with ecg graph. 3d illustration

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.